PAP
CRBP icon

Persistent Asset Partners’s Corbus Pharmaceuticals CRBP Stock Holding History

Persistent Asset Partners’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$722K Sell
76,919
-34,307
-31% -$325K 0.22% 84
2026
Q1 		$1.04M Buy
111,226
+104,639
+1,589% +$881K 0.39% 61
2025
Q4 		$53.6K Buy
+6,587
New +$81.3K 0.02% 291

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Persistent Asset Partners's CRBP Position: Q2 2026 in Review

Persistent Asset Partners reduced its Corbus Pharmaceuticals (CRBP) stake by 31% in Q2 2026, selling an estimated $325K and leaving 76,919 shares worth $722K. The position accounts for 0.22% of the portfolio, ranked #84.

Persistent Asset Partners first reported a position in CRBP in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.04M in Q1 2026. 107 funds tracked by Wall St. Rank hold CRBP as of Q2 2026.

  • Persistent Asset Partners held 76,919 shares of Corbus Pharmaceuticals worth $722K as of Q2 2026.
  • Persistent Asset Partners sold 34,307 Corbus Pharmaceuticals shares in Q2 2026, an estimated $325K.
  • Corbus Pharmaceuticals made up 0.22% of Persistent Asset Partners's portfolio in Q2 2026, its #84 holding.
  • Persistent Asset Partners first reported a position in Corbus Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Persistent Asset Partners's Corbus Pharmaceuticals position peaked at $1.04M in Q1 2026.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.